Introduction: Aim of this randomized prospective clinical trial is to compare two methods of antipyretics and evaluate their efficacy in controlling fever during the acute phase of brain damage. Methods: Twenty-two febrile comatose patients: 12 severe traumatic brain injury and 10 subarachnoid hemorrhage divided in 2 groups: Diclofenac low-dose infusion (10 patients) and extemporaneous boluses ofNSAIDs (CTRL, 12 patients). The primary outcome measure was length of time with temperature >38°C. Secondary outcome measures were: 1) to assess the effects of each antipyretic strategy on intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial pressure (MAP) and heart rate; 2) to monitor adverse effects of each antipyretic strategy. The baseline characteristics in the two treatment groups were similar. Results: Primary findings: percentage of time per patient with temperature >38°C was significantly lower (P < 0.0001) in the DCF group, 4% (0-22%), vs. 34% (8-56%) in CTRL group. In addition, mean T°, max T° were lower in DCF than inCTRL (P < 0.05). Secondary findings: CPP andMAPwere significantly higher in DCF group (P < 0.05) while ICP was not different (NS). However, if ICP pre randomization was < 25 mmHg, CTRL suffered a worst ICP (24 ± 11 vs. 16 ± 7 P ≤ 0.01), MAP (89 ± 10 vs. 104 ± 10 P ≤ 0.01) and CPP (75 ± 10 vs. 94 ± 17 P ≤ 0.01) compared to DCF. No differences between the two treatment were recorded when ICP ≥ 25 mmHg before randomization. There was no gastrointestinal or intracranial bleeding. Conclusions: Low dose DCF infusion is a potential useful strategy for a successful control temperature better than intermittent NSAIDs dosing, minimizing potentially braindamaging effects of fever. © Humana Press Inc. 2007.
Cormio, M., Citerio, G. (2007). Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care. NEUROCRITICAL CARE, 6(2), 82-89 [10.1007/s12028-007-0002-3].
Continuous low dose diclofenac sodium infusion to control fever in neurosurgical critical care
CORMIO, MANUELAPrimo
;CITERIO, GIUSEPPE
2007
Abstract
Introduction: Aim of this randomized prospective clinical trial is to compare two methods of antipyretics and evaluate their efficacy in controlling fever during the acute phase of brain damage. Methods: Twenty-two febrile comatose patients: 12 severe traumatic brain injury and 10 subarachnoid hemorrhage divided in 2 groups: Diclofenac low-dose infusion (10 patients) and extemporaneous boluses ofNSAIDs (CTRL, 12 patients). The primary outcome measure was length of time with temperature >38°C. Secondary outcome measures were: 1) to assess the effects of each antipyretic strategy on intracranial pressure (ICP), cerebral perfusion pressure (CPP), mean arterial pressure (MAP) and heart rate; 2) to monitor adverse effects of each antipyretic strategy. The baseline characteristics in the two treatment groups were similar. Results: Primary findings: percentage of time per patient with temperature >38°C was significantly lower (P < 0.0001) in the DCF group, 4% (0-22%), vs. 34% (8-56%) in CTRL group. In addition, mean T°, max T° were lower in DCF than inCTRL (P < 0.05). Secondary findings: CPP andMAPwere significantly higher in DCF group (P < 0.05) while ICP was not different (NS). However, if ICP pre randomization was < 25 mmHg, CTRL suffered a worst ICP (24 ± 11 vs. 16 ± 7 P ≤ 0.01), MAP (89 ± 10 vs. 104 ± 10 P ≤ 0.01) and CPP (75 ± 10 vs. 94 ± 17 P ≤ 0.01) compared to DCF. No differences between the two treatment were recorded when ICP ≥ 25 mmHg before randomization. There was no gastrointestinal or intracranial bleeding. Conclusions: Low dose DCF infusion is a potential useful strategy for a successful control temperature better than intermittent NSAIDs dosing, minimizing potentially braindamaging effects of fever. © Humana Press Inc. 2007.File | Dimensione | Formato | |
---|---|---|---|
Neurocrit Care 2007 Cormio.pdf
Solo gestori archivio
Dimensione
192.25 kB
Formato
Adobe PDF
|
192.25 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.